This work identifies a molecular mechanism that controls the onset of mitotic cell death, which is important for surveillance against defects in mitosis and the response to cancer drugs that target cell division.
INTRODUCTION
Anti-cancer drugs such as microtubule poisons arrest or delay cells in mitosis due to the action of the mitotic or spindle assembly checkpoint. This checkpoint normally prevents anaphase from occurring before all chromosomes are correctly bi-orientated on the metaphase spindle by inhibition of the anaphase-promoting complex or cyclosome (APC/C), a large E3 ubiquitin ligase complex that targets mitotic regulators such as securin and cyclin B1 for destruction by the proteasome (Primorac and Musacchio, 2013) . Cells that are arrested for a prolonged period in mitosis can undergo cell death by the process of apoptosis (Allan and Clarke, 2007; Gascoigne and Taylor, 2008) . The propensity for apoptosis is increased by the duration of the mitotic arrest (Bekier et al., 2009; Huang et al., 2009 ) whereas exit from mitosis generally reduces sensitivity to anti-mitotic drugs (Brito and Rieder, 2006; Gascoigne and Taylor, 2008) . Apoptosis can still occur after release from a prolonged delay in mitosis after longer-term changes including activation of signalling pathways and new protein expression (Colin et al., 2015; Uetake and Sluder, 2010) .
The intrinsic apoptotic pathway is activated when cytochrome c is released from mitochondria into the cytosol, where it forms a complex with Apaf-1 leading to the recruitment and activation of caspase-9, a cystyl-aspartame endoprotease. Caspase-9 in turn cleaves and activates the effector caspases -3 and -7, which act on multiple substrates to bring about the cellular changes associated with apoptosis, including cellular blebbing, chromatin condensation and internucleosomal DNA fragmentation (Budihardjo et al., 1999) . This pathway is controlled during mitosis by protein phosphorylation and the ubiquitin/proteasome-mediated destruction of regulators of the intrinsic apoptotic pathway; these mechanisms couple the control of apoptosis to the progression of mitosis (Clarke and Allan, 2009) . Caspase-9 is phosphorylated at an inhibitory site in mitosis by CDK1-cyclin B1, the major mitotic protein kinase, which thereby restrains apoptosis during normal mitosis and the initial stages of mitotic arrest. If metaphase is not successfully resolved then apoptosis is initiated during a prolonged mitotic arrest when the apoptotic signal overcomes the threshold set by caspase-9 phosphorylation (Allan and Clarke, 2007) . Conversely, the apoptotic signal is initiated when phosphorylation of the anti-apoptotic protein Mcl-1 at Thr92 by CDK1-cyclin B1 causes it to be degraded during a delay in mitosis (Harley et al., 2010; Wertz et al., 2011) . Stabilisation of Mcl-1 by abolition of Thr92 phosphorylation or mutation of a destruction box (D-Box) that is recognised by the APC/C inhibits apoptosis induced by microtubule poisons (Harley et al., 2010) . In addition, the related anti-apoptotic proteins Bcl-2 and Bcl-xL are phosphorylated and appear to be partially inhibited during Journal of Cell Science • Advance article mitosis (Terrano et al., 2010) . The slow degradation of cyclin B1 even though the spindle assembly checkpoint is active can lead eventually to inactivation of CDK1-cyclin B1 and slippage out of mitosis (Brito and Rieder, 2006) . Whether or not apoptosis is initiated during mitotic arrest is likely to depend upon relative changes in the activities of CDK1-cyclin B1 and regulators of apoptosis during the mitotic arrest (Allan and Clarke, 2007; Gascoigne and Taylor, 2008) .
Although caspase-3 and caspase-7 do not appear to be regulated directly during mitosis by phosphorylation, these enzymes might also be controlled through interacting proteins. One candidate is XIAP (X-linked inhibitor of apoptosis), a protein of the IAP family that is capable of inhibiting activated caspases-3, -7 and -9 by direct binding (Deveraux et al., 1999; Takahashi et al., 1998) . XIAP can also function as an E3 ubiquitin ligase and as a signal transduction intermediate (Eckelman et al., 2006; Lu et al., 2007) . XIAP is overexpressed in a number of cancer cell lines and its over-expression correlates with increased resistance to chemotherapeutic drugs, including inhibitors of mitosis (Durie et al., 2011; Holcik et al., 2000; Tamm et al., 2000) . XIAP is regulated acutely by post-translational modifications that can determine sensitivity to cellular stresses: phosphorylation at serine 87 by Akt reduces XIAP autoubiquitylation and stabilises the protein in cisplatin-treated cells (Dan et al., 2004 ) whereas phosphorylation at serine 430 by TANK-binding kinase 1 (TBK1) or I B kinase IKK results in the auto-ubiquitylation and subsequent proteasomal degradation of XIAP after viral infection of cells (Nakhaei et al., 2012) . However, it has been unclear if regulation of XIAP plays a role in controlling apoptosis during mitosis. In this study, we show that XIAP is phosphorylated at specific sites during mitosis by CDK1-cyclin B, which inhibits the antiapoptotic activity of XIAP and makes mitotic cells more sensitive to pro-apoptotic signals.
Thus, XIAP plays a key role in coupling the control of apoptosis to the progression of mitosis.
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RESULTS
XIAP restrains apoptosis in response to prolonged mitotic arrest
We tested the role of human XIAP in the control of apoptosis in response to the disruption of mitosis. We found that ablation of XIAP in U2OS cells by siRNA promoted the cleavage and activation of caspase-3, a major effector of apoptosis (Figure 1A 
XIAP is phosphorylated during mitosis
Although these results established that XIAP plays a role in the control of apoptosis in response to prolonged mitotic arrest, we did not observe any periodic changes in the levels of the protein during the cell cycle (Supplementary figure 2A) , which might indicate a mechanism of regulation. Similarly, the level of XIAP was maintained during a prolonged mitotic arrest until exit from mitosis and the induction of apoptosis (Supplementary figure   2B ). To determine if XIAP is regulated post-translationally by phosphorylation during mitosis, we treated HeLa and U2OS cells with nocodazole and compared isolated rounded-up mitotic cells with adherent interphase cells. Modification of XIAP leading to retardation of the protein was not readily detected on Western blots of conventional SDS-PAGE gels ( Figure 2A ). However, modification of XIAP in mitotic cells was clearly apparent when gels were supplemented with PhosTag, an acrylamide-bound ligand that preferentially retards the migration of phosphorylated proteins (Kinoshita et al., 2006 ). There was one major and one minor retarded form of XIAP in rounded-up mitotic cells, but not in adherent interphase cells also treated with nocodazole nor in untreated asynchronous cells, demonstrating that XIAP was phosphorylated on at least two sites specifically during mitosis, with one site predominating ( Figure 2A ). XIAP was also phosphorylated in mitotic HCT116 and DLD1
human colorectal cancer cells with a very similar pattern of phosphorylated forms ( Figure   2B ).
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The mitotic phosphorylation of XIAP was reversed in parallel with cyclin B degradation when U2OS cells were released from mitotic arrest by washing out nocodazole.
Dephosphorylation of XIAP was prevented by the proteasome inhibitor MG132, which prevents the degradation of cyclin B even in the absence of the checkpoint signal and maintains cells in mitosis ( Figure 2C ). When mitotically-arrested cells were maintained in nocodazole having been synchronised in the period of the arrest, phosphorylated forms of XIAP progressively accumulated over 2-6 hours. MG132 did not alter the pattern of phosphorylated forms during mitotic arrest, indicating that both hypo-and hyperphosphorylated XIAP were stable during the period of arrest ( Figure 2D ).
Purified recombinant XIAP expressed as a fusion protein with glutathione-Stransferase (GST-XIAP) was also phosphorylated in a mitotic HeLa cell extract, with one major retarded form observed on PhosTag gels that accumulated over 30 mins ( Figure 2E ).
Formation of phosphorylated XIAP form was inhibited by calf intestinal phosphatase (CIP) or inhibition of cyclin-dependent kinases (CDKs) by purvalanol A (PA) ( Figure 2F ), indicating mitotic phosphorylation of this major site is dependent on CDK1 in complex with cyclin B rather than cyclin A, which is lost from mitotically-arrested cells prior to preparation of the extract.
Identification of sites of mitotic phosphorylation in XIAP
Human XIAP contains four serine/threonine residues (Ser40, Ser87, Thr180 and Thr359) that are followed immediately by a proline residue, a characteristic of phosphorylation sites targeted by proline-directed kinases such as CDK1-cyclin B. Ser40 has been identified in a global analysis of phosphorylation sites (Mertins et al., 2013) and Ser87 has been shown to be phosphorylated by Akt (Dan et al., 2004) . To analyse these potential mitotic phosphorylation sites, we mutated each residue to a non-phosphorylatable alanine residue and produced the resulting proteins by in vitro transcription and translation (IVT) in mammalian reticulocyte lysate. When incubated in mitotic HeLa cell extract, the wild-type, S87A, T180A
and T359A proteins were all phosphorylated whereas mutation of Ser40 abolished the formation of the predominant phosphorylated form ( Figure 3A ), indicating that this residue was the major phosphorylation site.
In another approach to determine the site(s) of mitotic phosphorylation, XIAP stably expressed as a fusion with green fluorescent protein (GFP-XIAP) was immunoprecipitated from mitotic nocodazole-treated U2OS cells. We confirmed that the protein was indeed phosphorylated in mitosis, exhibiting one major and one minor phosphorylated form ( Figure   Journal of Cell Science • Advance article 3B), before analysis of tryptic peptides by nano LC-MS/MS on a LTQ-Obitrap Velos mass spectrometer in combination with a neutral loss scan on a 4000 QTRAP mass spectrometer to detect phosphorylated peptides. Two phosphorylation sites were identified, with a major peptide phosphorylated on Ser40 and a less abundant peptide phosphorylated on Thr180 ( Figure 3C ). Taking into account the proportion of modified XIAP detected on PhosTag gels, this data shows that approximately 50% of XIAP is phosphorylated at Ser40 in cells arrested in mitosis, with additional phosphorylation at T180 at a lower stoichiometry.
XIAP is phosphorylated at serine 40 in mitosis
To facilitate analysis of the phosphorylation of Ser40 in XIAP, a specific polyclonal antibody was raised by inoculation with a synthetic peptide that included the phosphorylated site.
Antibodies were purified from serum by negative selection against the dephosphorylated peptide followed by positive selection against the phosphopeptide. Selectivity was tested on dot blots where BSA-conjugated peptides were probed using purified antibodies ( Figure 4A ).
The pS40 antibody detected IVT XIAP phosphorylated in mitotic HeLa cell extracts, whereas the S40A mutant was not detected. Thus, the antibody is specific for phosphorylated Ser40 and no other phosphorylation site in XIAP ( Figure 4B ). Endogenous XIAP phosphorylated on Ser40 was detected in U2OS cells arrested in mitosis with nocodazole; the specific polypeptide was identified by its ablation by prior depletion of XIAP by siRNA transfection ( Figure 4C ).
We confirmed that Ser40 was phosphorylated in GFP-XIAP expressed in U2OS cells arrested in mitosis with nocodazole. Analysis of the migration of GFP-XIAP on PhosTag gels ( Figure 4D ) showed that mutation of Ser40 inhibited the formation of not only the major phosphorylated form but also other minor phosphorylated forms. This indicates that Ser40 is necessary for phosphorylation at one or more less abundant sites, most likely including Thr180. GFP-XIAP was phosphorylated on Ser40 in mitotic U2OS cells but not in untreated adherent interphase cells or nocodazole-treated adherent cells ( Figure 4E ). We unequivocally identified this phosphorylated form as GFP-XIAP by its immunoprecipitation from cell extracts prior to Western blotting ( Figure 4F ).
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XIAP is phosphorylated at serine 40 by CDK1-cyclin B
The previous observation that purvalanol A inhibited the phosphorylation of GST-XIAP in mitotic HeLa cell extract ( Figure 2F ) indicated that phosphorylation was dependent on a CDK1-cyclin B. Similarly, phosphorylation of IVT XIAP incubated in mitotic HeLa cell extract and analysed on a PhosTag gel ( Figure 5A ) was inhibited by purvalanol A and RO3306, a more selective inhibitor that specifically targets CDK1 and not DYRK1A at the concentration used (Vassilev et al., 2006) . We confirmed that CDK inhibitors, but not other kinase inhibitors including wortmannin, inhibited the phosphorylation of Ser40 in XIAP in mitotic extracts ( Figure 5B ). Futhermore, XIAP was phosphorylated on Ser40 in a timedependent manner by incubation with purified CDK1-cyclin B1 ( Figure 5C ), showing that this kinase catalyses the phosphorylation of XIAP directly.
Mutation of serine 40 to aspartate inhibits XIAP binding to active effector caspases.
XIAP is perhaps best known for its ability to bind to and inhibit activate caspases (Deveraux et al., 1999; Takahashi et al., 1998) . To test whether mitotic phosphorylation of XIAP at Ser40 could affect this function we carried out an in vitro binding assay utilising a potentially phosphomimetic aspartate mutant (S40D) as a surrogate for phosphorylated XIAP and comparing its ability to bind cleaved effector caspases with that of the non-phosphorylatable mutant S40A. GFP-XIAP S40D and S40A proteins produced in stably transfected U2OS cells were incubated with HeLa cell extract (S100) pretreated with cytochrome c and dATP to generate cleaved caspases (Li et al., 1997) . Western blotting analysis of proteins coprecipitating from the extract demonstrated that XIAP S40D was less efficient at binding to cleaved caspase 7 and cleaved caspase 3 than the S40A protein ( Figure 6 ). In contrast, both XIAP proteins exhibited a similar ability to bind to Smac, a protein that binds to and neutralises XIAP function (Du et al., 2000; Verhagen et al., 2000) . This shows that the S40D protein is competent for some aspects of XIAP function but is inhibited in its ability to bind activated effector caspases, indicating that mitotic phosphorylation of XIAP at Ser40 restrains its ability to inhibit caspase activity.
Modification of XIAP at serine 40 inhibits its anti-apoptotic activity
The inhibitory effect of the S40D mutation on the ability of XIAP to bind active caspases strongly suggests that phosphorylation of Ser40 in XIAP regulates its anti-apoptotic activity.
To test this possibility, we first characterised the stability of wild type and phosphorylation site mutant GFP-XIAP proteins during interphase and mitotic arrest. We found that GFPJournal of Cell Science • Advance article XIAP S40A and S40D proteins, like the wild-type protein, were expressed at a constant level during mitotic arrest, indicating that the stability of the protein during mitosis was not affected by phosphorylation at this site ( Figure 7A ). Consistent with results discussed above ( Figure 2D ), phosphorylation of Ser40 detected by the specific antibody gradually increased over 2-6h of arrest (Supplementary figure 3) . Importantly, while expression of either wildtype XIAP or the S40A mutant strongly inhibited the induction of apoptosis after prolonged treatment with nocodazole, the S40D mutant was much less effective and produced no apparent inhibition of apoptosis ( Figure 7B, Supplementary figure 4A) . The difference between the S40A and S40D proteins strongly suggests that phosphorylation of Ser40 inhibits the anti-apoptotic activity of XIAP. The similar effect of wild-type and S40A XIAP expression is consistent with the dominant inhibitory activity of the non-phosphorylated protein which is strongly elevated in both cases.
To determine if modification of XIAP at Ser40 affects the acute apoptotic response during mitosis when phosphorylation occurs, we analysed the induction of cell death in individual mitotic cells by live-cell imaging. U2OS cells arrested in mitosis by 250 ng/ml nocodazole were tracked for around 70 h after entry into mitosis, by which time they had either slipped from mitosis, blebbing transiently and flattening down as they entered interphase (denoted survival), or had undergone rigorous blebbing followed by stasis (mitotic cell death) ( Figure 7C, Supplementary figure 4B ). About 55% of control cells transfected with an empty vector (EV) underwent mitotic cell death and cells that expressed S40D mutant of XIAP showed only a slight reduction in cell death to 40% of control. By contrast, cells expressing either wild-type of S40A mutant of XIAP showed a strong reduction in mitotic cell death (<5% of control) ( Figure 7D ), indicating that phosphorylation of XIAP at Ser40 inhibits its activity during mitosis and promotes mitotic cell death.
DISCUSSION
The induction of apoptosis during mitosis provides a mechanism to selectively kill rogue cells that have failed to undergo chromosome segregation successfully and on schedule. This pathway also provides opportunities for the selective killing of cancer cells through drugs that interfere with mitosis, including microtubule poisons such as taxanes that prevent the proper attachment of chromosomes to spindle microtubules and cause a prolonged arrest in mitosis due to the activity of the spindle assembly (mitotic) checkpoint. Importantly, there are distinct post-translational mechanisms that control apoptosis during mitosis that facilitate Journal of Cell Science • Advance article drug-induced cell killing, perhaps especially in cancer cells that have sustained cellular stress but in which apoptosis is actively suppressed.
In this report we have identified a mechanism that controls the induction of cell death in mitotically-arrested cells through a key regulator, XIAP. Our results indicate that phosphorylation of XIAP at a single major site by the master mitotic kinase, CDK1-cyclin B, negates the ability of XIAP to bind to active effector caspases and thereby reduces the threshold for apoptosis (Figure 8 ). We show that approximately 50% of the endogenous XIAP protein is phosphorylated at the inhibitory site, Ser40 (Figure 3) , suggesting that the remaining protein that is not phosphorylated at this site continues to provide a restraint, albeit reduced, so that when XIAP is completely ablated, apoptosis is increased further (Figure 1 ).
We propose that this mechanism is important for the control of cell death during mitotic arrest, because it reduces a downstream barrier to apoptosis once caspases-3/7 have been The sensitisation of mitotically arrested cells to apoptosis can be hypothesised to actively remove cells that become severely delayed in mitosis due to problems with chromosome segregation, supernumerary centrosomes or even aneuploidy. This would provide a mechanism to suppress the propagation of chromosome abnormalities (Figure 8 ).
Cancer cells exhibiting such defects, however, have presumably gone through a selection crisis in which the mechanism of apoptosis during mitosis is actively supressed. Two levels of the pathway at which this might well occur are the over-expression of anti-apoptotic Bcl-2 family proteins, preventing cytochrome c release and caspase activation, or XIAP overexpression, blocking the action of caspases. At present it is unclear if aberrant changes in the post-translational regulation of these components also contribute to the suppression of mitotic cell death in cancer cells, but if this is the case then targeting these mechanisms could activate apoptosis particularly well in such stressed cells.
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The regulation of XIAP by CDK1-cyclin B illustrates the close integration of the control of apoptosis with the progression of mitosis. In addition to XIAP, Mcl-1 is destroyed by proteolysis following phosphorylation by CDK1-cyclin B (Harley et al., 2010; Wertz et al., 2011) , and the related anti-apoptotic proteins Bcl-2 and Bcl-xL may be directly inhibited by mitotic phosphorylation (Terrano et al., 2010) . Opposing these pro-apoptotic events, we have shown that caspase-9 is inhibited by phosphorylation during normal mitosis and in the early stages of mitotic arrest (Allan and Clarke, 2007) . The importance of the inhibition of XIAP by mitotic phosphorylation might be that it removes a downstream brake on apoptosis, resulting in one major point of regulation (caspase-9 activation) that permits the induction of apoptosis after a prolonged arrest. Anti-cancer drugs that target mitotic cells appear to exploit this mechanism to initiate mitosis by arresting or delaying them in mitosis long enough to overcome the temporal restraint to caspase activation. Cells that do not undergo full apoptosis from the mitotic state may nevertheless carry a signal caused by caspase-dependent DNA damage that can subsequently determine long-term cell fate after release into interphase even though a higher threshold for apoptosis has been restored (Colin et al., 2015) (Figure 8 ). Our results further emphasise that cell death during mitosis is a form of caspase-dependent apoptosis, albeit one under mitosis-specific post-translational controls.
MATERIALS AND METHODS
Cell culture and cell extracts
HeLa (Ohio) and U2OS (HTB96) cell lines were obtained from Cancer Research UK Laboratories, London, UK. HCT116 parental and XIAP knock-out cell lines were purchased from Horizon Discovery Ltd., Cambridge, UK. All cell lines were confirmed as negative for mycoplasma infection. Cells were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) foetal bovine serum (Biosera) and 1% (v/v) Penicillin-Streptomycin (Invitrogen) at 37 C and 5% CO2. U2OS cells stably expressing GFP-XIAP proteins were generated by transfection with pEGFP-XIAP vector containing a G418 resistance marker. Cells were grown for 2-3 weeks with 800 g/ml G418 Geneticin (Invitrogen) and maintained in 400 g/ml G418. Cell extracts were prepared from mitotic or asynchronous HeLa cells at a protein concentration of 6-10 mg/ml in EBS [80 mM -glycerophosphate-HCl (pH 7.2), 20 mM EGTA-NaOH (pH 8.0), 15 mM MgCl2, 100 mM sucrose, 1 mM DTT, 1 mM PMSF] as described previously (Harley et al., 2010) . HeLa cell cytosolic S100 extracts were supplied at a protein concentration of 8 mg/ml in extract buffer [10mM Hepes-KOH (pH 8.5), 10mM
KCl, 10mM MgCl2, 0.5mM DTT] (Computer Cell Culture Centre, Mons, Belgium).
XIAP knock down by siRNA
Four RNA oligonucleotides that made up the siGENOME SMARTpool XIAP siRNA (Thermo Fisher Scientific) were tested individually. Two of the four oligonucleotides that resulted in the most efficient depletion of XIAP were used together in future experiments.
The two XIAP siRNA oligos and the luciferase control siRNA were: XIAP siRNA 1: 5'-GCA CGG AUC UUU ACU UUG-3' XIAP siRNA 2: 5'-GAA CUG GGC AGG UUG UAG A-3' Luciferase siRNA: 5'-CGU ACG CGG AAU ACU UCG ATT-3' U2OS cells were transfected with the oligos using Lipofectamine 2000 (Invitrogen) and incubated for 48h. 250 ng/ml nocodazole was then added for a further 48h as required.
Western blotting
Antibodies were used as described in Supplementary Table 1 .
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Generation of a polyclonal antibody specific for XIAP phosphorylated at Ser40
Rabbits were inoculated with the phosphorylated peptide FANFPSGS*PVSASTL (where S* represents the phosphorylated residue) by Moravian Biotechnology. A phospho-specific antibody, pS40 XIAP, was purified from the serum obtained after a second inoculation on a column of phosphorylated peptide coupled to Reactigel beads (Pierce Biotechnology), eluted with 0.1 M Glycine-HCl (pH 2.5) which was neutralised with the addition of 1.5 M Tris-HCl (pH 8.5) supplemented with 100 g/ml BSA, 50% glycerol and 0.05% sodium azide, and stored at -20 C.
Phosphorylated or non-phosphorylated peptide was coupled to immunoglobulin-free BSA (Sigma-Aldrich) using 50% (w/v) glutaraldehyde solution (Sigma-Aldrich) diluted in PBS. The BSA-conjugated peptide solutions were serially diluted in PBS, spotted onto nitrocellulose membrane and air-dried before being incubated in Western blocking buffer.
They were then incubated with 1:500 diluted phospho-specific antibody overnight at 4 C, followed by washes and secondary antibody probing.
Detection of active caspase-3
Cells on coverslips or glass slides were permeabilised by incubating in ice-cold 80% ethanol for 15 minutes, and followed by two washes in PBS. Cells were blocked in 5% BSA/0.2% Triton-X-100 in PBS for 20 minutes at room temperature, before they were incubated with anti-cleaved caspase-3 antibody (Cell Signalling) at 1:400 dilution in 1% BSA/0.2% Triton-X-100 in PBS at room temperature for 1 h. After two 5-minute washes with 0.2% Triton-X-100/PBS on a rotary shaker, cells were incubated with 1:200 diluted TRITC-anti-rabbit secondary antibody (Dako) and 250 ng/ml DAPI (Sigma) in 1% BSA/0.2% Triton-X-100 in PBS in the dark at room temperature for 1 h. This was followed by two 5 min washes with 0.2% Triton-X-100/PBS and one 5 min wash with PBS on a rotary shaker. Slides were mounted with mounting media (Dako), air dried and kept at 4°C in the dark until viewed under the microscope.
Microscopy
Fixed cells were visualised using Zeiss Axiovert 100 microscope with specific filters for the excitation of fluorophores. Images were taken at 63 magnification using Openlab software.
For live-cell imaging, cells were imaged every 10 min in a heated chamber on a Zeiss Axiovert 200M microscope. Images were acquired using a C4742-80-12AG camera Journal of Cell Science • Advance article (Hamamatsu) and µmanager software and were processed using ImageJ Fiji. Analysis was carried out on cells that were arrested in mitosis for at least 6 h with cell death being defined by cell morphology and cessation of movement.
Flow cytometry
Cells stained with propidium iodide were analysed on a FACS flow cytometer (Becton Dickinson) on the FL3 channel. A minimum of 10 4 cells were analysed for each sample. Data were displayed as dot plots and histograms showing the cell cycle phases and subG1 population using FlowJo software.
GFP-XIAP precipitation from cells
U2OS cells stably expressing GFP or GFP-XIAP were treated with 100 ng/ml nocodazole for 17 hours. The asynchronous cells from the untreated plate and the mitotically arrested cells from the nocodazole treated plates were washed twice in cold PBS, and lysed in cold GFP lysis buffer [10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 5 mMglycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 1 g/ml each of aprotinin, leupeptin and pepstatin A, 0.2% CHAPS]. The protein concentration of the lysates was adjusted to 1 mg/ml with GFP lysis buffer. 300 g lysate was mixed with 10 l pre-washed GFP-Trap beads (ChromoTek) for each sample, and incubated at 4°C for 1 h on a rotator.
The beads were pelleted by centrifugation at 4°C, washed once with GFP lysis buffer followed by two washes with 10 mM Tris-HCl (pH 7.5). Samples were analysed by SDS-PAGE and Western blotting.
In vitro phosphorylation assays
GST-XIAP was expressed from the pGEX-6P-1 vector in E.coli BLR(DE3) competent cells addition of an equal volume of 2 SDS lysis buffer, 5% -ME and 0.05% bromophenol blue.
Due to the presence of EGTA in the cell extract EBS buffer, which would interfere with PhosTag reagent, an equal molar concentration of MnCl2 was added to the loading samples
that were going to be tested on PhosTag gels. Samples were boiled for 4 min, then analysed by SDS-PAGE and Western blotting.
In vitro binding assay
HeLa S100 extract (4mg) was incubated with 10µM cytochrome c and 1mM dATP together with ATP regenerating system (1mM ATP, 10µg/ml creatine kinase, 5mM creatine phosphate), 30 C, 3 h. U2OS cells stably expressing GFP-XIAP S40A or S40D were lysed in GFP-Trap buffer [10mM Tris (pH 7.5), 150mM NaCl, 0.5mM EDTA, 0.5% NP40]. 2mg lysate was diluted 2:3 with dilution buffer (GFP-Trap buffer without NP40) and incubated with 25µl GFP-TrapM beads (ChromoTek), 4 C, 1 h with rotation. Beads were isolated using a magnet (BioRad) and washed 3 times in GFP-Trap buffer diluted as above followed by one wash in dilution buffer. GFP-XIAP beads were then incubated with S100/cytochrome c/dATP reactions at room temperature, 90 min with rotation. Beads were then isolated, washed as above and boiled in SDS gel-loading buffer.
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